| Ms Deborah Joan Till, ANP | |
|
250 E Fireweed Ave, Alaska Veterans And Pioneer Home, Palmer, AK 99645-6638 | |
| (907) 745-4242 | |
| (907) 745-0230 |
| Full Name | Ms Deborah Joan Till |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 250 E Fireweed Ave, Palmer, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730350315 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 15140-269 (Alaska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Deborah Joan Till, ANP 250 E Fireweed Ave, Alaska Veterans And Pioneer Home, Palmer, AK 99645-6638 Ph: (907) 745-4242 | Ms Deborah Joan Till, ANP 250 E Fireweed Ave, Alaska Veterans And Pioneer Home, Palmer, AK 99645-6638 Ph: (907) 745-4242 |
News Archive
The Center for Global Health Policy's "Science Speaks" blog reports on a meeting held last week "to discuss the problem of U.S. and global tuberculosis [TB] drug shortages."
Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care had examined their added benefit in a dossier assessment completed in April 2015.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll a second allotment of 54 patients in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol (CAP).
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.
› Verified 6 days ago
Katie M Montano, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Mrs. Jennifer Gail Vinette, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Ms. Jessica Lynn Bray, ANP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2490 S Woodworth Loop Ste 200, Palmer, AK 99645 Phone: 907-861-6700 | |
Dr. Stephanie Anne Olah Packard, APRN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1734 Prospect Dr, Palmer, AK 99645 Phone: 907-745-3380 Fax: 907-746-7471 | |
Sarah Wood Johanson, MSN, ACNP-BC, RNFA Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2490 S Woodworth Loop, Suite 450, Palmer, AK 99645 Phone: 907-745-9401 Fax: 907-746-2655 | |
Carol Ann Sant, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Ms. Kathleen Marie Megha Hammaker, M.S.,R.N.,A.N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 425 E Dahlia Ave, Ste Mb, Palmer, AK 99645 Phone: 907-746-4412 Fax: 907-746-5539 |